Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Candesartan

A sartan patented in 1990 and approved in 1997 for hypertension and heart failure. It is taken as a prodrug, candesartan cilexetil, which enzymes in the intestinal wall convert into the active molecule during absorption. This family brings together pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It is considered one of the most potent AT1 receptor blockers by weight, and researchers have also studied it for preventing migraine.

Candesartan-d4Isotopically labelledCandesartan-d4Cat. No. P-C018-014CAS 1346604-70-3
Candesartan-d5Isotopically labelledCandesartan-d5Cat. No. P-C018-015CAS 1189650-58-5

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.